Arnould Laurent, Caron Yves, Sigal-Zafrani Brigitte
Service de Pathologie, Centre Georges-François Leclerc, 1 rue Professeur Marion, BP 77980, 21079 Dijon Cedex.
Ann Pathol. 2003 Dec;23(6):534-46.
As a consequence of increased screening mammography, ductal carcinoma in situ represents a growing percentage of breast cancer diagnoses. The management of per-cutaneous biopsies as well as wire-localized surgical biopsies is a difficult task for pathologists. In this Article, we describe the diagnostic criteria of these lesions as well as the histopathological characteristics of their two principal differential diagnoses: atypical ductal hyperplasia and micro-infiltrating carcinoma. We also detail the utility of immunohistochemistry in the diagnosis of these lesions. This paper reviews the accepted prognostic factors for ductal carcinoma in situ and describes the important techniques needed to characterize them (grade and extent, status of margins and exclusion of microinvasion). Correct handling of pathological specimens, as detailed here, is one of the main keys for therapeutic success with ductal carcinomas in situ. Indeed, if dealt with adequately, such lesions should almost never affect the patient's long-term survival.
由于乳腺钼靶筛查的增加,导管原位癌在乳腺癌诊断中所占的比例越来越大。对于病理学家来说,经皮活检以及金属丝定位手术活检的处理是一项艰巨的任务。在本文中,我们描述了这些病变的诊断标准以及它们两个主要鉴别诊断的组织病理学特征:非典型导管增生和微浸润癌。我们还详细介绍了免疫组织化学在这些病变诊断中的应用。本文回顾了公认的导管原位癌预后因素,并描述了对其进行特征化所需的重要技术(分级和范围、切缘状态以及微浸润的排除)。如本文所述,正确处理病理标本是导管原位癌治疗成功的关键之一。事实上,如果处理得当,此类病变几乎不会影响患者的长期生存。